ResearcherLoma Linda UniversityActive in the last 2 years

Yi Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6917-184X; OpenAlex author ID A5052215978. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper

Papers 1

Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRAS G12D-mutated pancreatic cancer. Last author DOI 10.1186/s40164-025-00669-w ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Huynh Le Cao · 1 shared paper, 2025 · strength 0.19
- Paper Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRAS G12D-… DOI 10.1186/s40164-025-00669-w ↗
Jeffrey Xiao · 1 shared paper, 2025 · strength 0.19
- Paper Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRAS G12D-… DOI 10.1186/s40164-025-00669-w ↗
Diana L. Hanna · 1 shared paper, 2025 · strength 0.19
- Paper Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRAS G12D-… DOI 10.1186/s40164-025-00669-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.